Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid and methotrexate for secondary osteoporosis in rheumatoid arthritis
ChiCTR1800019290Phase 2Completed
- Sponsor
- Lianbo Pharmaceutical
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoledronic acid and methotrexate in rheumatoid arthritis (RA) and osteoporosis (3 arms), sponsored by Lianbo Pharmaceutical. Primary endpoints: C-reactive protein, Erythrocyte sedimentation rate and 2 more. Started Jan 2014; status: completed.
02
Drugs
zoledronic acidmethotrexate
03
Conditions
rheumatoid arthritis (RA)osteoporosis
Beyond the preview
Go deeper on ChiCTR1800019290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019290.